title: Self-perception of quality of life in patients treated with antipsychotics.
abstract: OBJECTIVE
  Despite extensive research, normal functionality remains problematic in patients with schizophrenia. Issues such as quality of life, subjective well-being, or psychosocial performance are currently objectives of interest. There are limited data collected prospectively on patients' perception of quality of life as compared between treatment groups, especially in developing countries. The aim of the present study was to analyze the evolution of patients' reported quality of life in patients with schizophrenia or related disorders treated with antipsychotics, in naturalistic settings.
  
  
  METHODS
  The study was designed as a 12-month prospective observational study of 131 subjects with schizophrenia or related disorders treated with haloperidol, olanzapine, risperidone, quetiapine, or aripiprazole, recruited from consecutive hospitalized patients in a psychiatry department.
  
  
  RESULTS
  The mean scores for patients' reported quality of life and its components and for satisfaction with treatment had a favorable evolution, but increases were of reduced magnitude. The differences among treatment groups were not statistically significant, with few exceptions. A great variability of data was found.
  
  
  CONCLUSIONS
  Studies with a stratified analysis by factors influencing quality of life perceptions in this category of patients might allow the identification of differences, if any, between antipsychotics in this domain.
authors.forename: Lorena
authors.initials: L
authors.lastname: Dima
authors.forename: Daniel
authors.initials: D
authors.lastname: Vasile
authors.forename: Liliana
authors.initials: L
authors.lastname: Rogozea
authors.forename: Muhammad
authors.initials: M
authors.lastname: Zia-Ul-Haq
authors.forename: Shazia Anwer
authors.initials: SA
authors.lastname: Bukhari
authors.forename: Marius
authors.initials: M
authors.lastname: Moga
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000145:classification; D057186:Comparative Effectiveness Research; D005260:Female; D006801:Humans; D007297:Inpatients / Q000523:psychology / Q000706:statistics & numerical data; D008297:Male; D008603:Mental Health; D008875:Middle Aged; D011446:Prospective Studies; D011567:Psychiatric Department, Hospital / Q000706:statistics & numerical data; D011569:Psychiatric Status Rating Scales; D011788:Quality of Life / Q000523:psychology*; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D012649:Self Concept; D012919:Social Behavior; D066107:Social Skills
chemical_list: D014150:Antipsychotic Agents